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Steven O’ReillyAbstract
MicroRNAs (miRNAs) are small, non-coding RNAs that
mediate mRNA cleavage, translational repression or
mRNA destabilisation and are around 22–25 nucleotides
in length via partial complementary binding to the 3′
untranslated region in target transcripts. They are
master regulators of gene expression. Fibrosis is an
important cause of morbidity and mortality in the
world, and there are currently no accepted treatments
for fibrosis. Many novel miRNAs are now associated with
fibrosis, both organ-specific and systemic, as in the
prototypical fibrotic disease systemic sclerosis. Recently,
the targets of these altered miRNAs have been validated
and defined new biochemical pathways. Dysregulated
miRNAs are amenable to therapeutic modulation. This
review will examine the role of miRNAs in fibrosis and
the opportunities and challenges of targeting them.virtually all cell processes and that they also play a key roleBackground
Chronic inflammation often leads to tissue fibrosis [1].
Fibrosis is a wound-healing response that results from
inflammation and results in excessive extracellular matrix
(ECM) deposition that ultimately impairs the function of
the tissue and organ. Fibrogenesis is choreographed by a
variety of cytokines, chemokines and inflammatory cells.
Various insults can cause tissue damage, including infec-
tious agents, mechanical damage, heat and autoimmune
disease. This stimulates a repair process that leads to
repair of the tissue to restore homeostasis, and if not
controlled appropriately this can lead to aberrant repair
processes and ultimately fibrosis. In most cases, the in-
jury is resolved and the fibrogenic response is controlled;
however, if not, there is excessive ECM deposition and tis-
sue remodelling and ultimately loss of function. In many
diseases, fibrosis plays a major role, such as in liver orCorrespondence: steven.oreilly@northumbria.ac.uk
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osis (SSc), multiorgan fibrosis can lead to death [1] and
these comprise a large proportion of deaths. Although a
large number of diseases have a fibrotic pathology and
represent a huge global burden, there are no currently
licenced treatments. The paucity of therapeutic options
likely reflects our lack of understanding of the under-
lying mechanism; however, in recent years, new targets
have been discovered. MicroRNAs (miRNAs) are small
(between 21 and 25 nucleotides long) non-coding
RNAs that mediate mRNA repression or destabilisation
and lead to translational repression and thus are im-
portant regulators of gene expression. MiRNAs initially
were discovered in the nematode worm Caenorhabditis
elegans but now are known to be highly conserved
across species. They regulate gene expression post-
transcriptionally and are both cell- and context-dependent.
Recent evidence has suggested that miRNAs play a role in
in many diseases, including fibrosis. It is now known that
in the human genome it is composed of surprisingly few
genes, and the complexity of gene expression is now recog-
nised to be orchestrated by epigenetics. Over 60 % of all
mRNAs are predicted targets of miRNAs [2] and thus their
regulation in fibrosis development is significant. This re-
view will examine the role of miRNA in fibrosis and the
possibility of these being targeted therapeutically and the
strategies to do so.MiRNAs
Unlike small interfering RNA (siRNA), miRNAs mediate
their effects preferentially through imperfect base pairing
with sequences in the 3′ untranslated region (UTR) of
their target mRNAs. A region in the miRNA known as
the seed region is important for repression of the target
mRNA. The imperfect binding of the miRNA to the
mRNA means that one miRNA can regulate many genes,
and over 60 % of mRNAs are predicted to be targeted by
miRNAs by computational prediction [2]. Many software
programs publically available to determine targets of givenistributed under the terms of the Creative Commons Attribution 4.0 International
by/4.0/), which permits unrestricted use, distribution, and reproduction in any
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cognate targets of miRNAs by conserved binding sites.
Such databases include TargetScan (www.targetscan.org).
Although these programs are useful, they are not abso-
lutely correct and undoubtedly have false positives in
there. There can be large differences in targets using dif-
ferent target prediction software. Furthermore, it has been
found that miRNAs can target 5′ UTRs and it is now ap-
preciated that they may actually be more promiscuous
than first thought, underscoring their importance in post-
transcriptional regulation. MiRs often target mRNAs that
govern the same pathway that results in modulation of the
pathway.
Fibrosis signalling
The ultimate target cells in fibrosis are the fibroblasts
where it produces a surfeit of ECM that ultimately im-
pairs normal functioning of the tissue and organ. In-
flammation is a key component of fibrosis and many
cytokines and chemokines are involved in orchestrating
this. Although there are many diverse proteins involved,
transforming growth factor-beta (TGF-β) is considered
the most important (see below). Other cytokines such
as interleukin (IL)-6, IL-1, IL-13 and inflammasome
components are also considered important mediators
in disease pathogenesis. Also, molecules such as the
neurotransmitter serotonin are important in mediating
fibrosis but these may also lie upstream of TGF-β and
converge on this molecule. Clearly, all these molecules
may themselves regulate the expression of miRNAs
involved in fibrosis. Table 1 demonstrates miRNAs in
fibrosis and their confirmed targets.
miRNA29 as a ‘master fibromiRNA’ regulator
The exact relative contribution of miRNAs to fibrosis
and the bona fide targets are not fully known. MiRNAs
can be either pro- or anti-fibrotic. However, one miRNATable 1 MicroRNAs in fibrosis
MicroRNA Target gene
17-5p Smad7
21 Sprouty homolog-1, PTEN, SMAD7, STAT3, PPAR-α
29, a,b,c Collagen1A1, 1A2, 4A5, FBN, ELN1, PDGFR, TAB1, ADAM
33a PPAR-α
122 P4HA1
129-5p Collagen1A1
132 MeCP2
133a Collagens
192 ZEB1
199b DYRK1A
199a-5p CAV1
214 CTGFthat has emerged as a master regulator appears to be
miRNA-29. This is a family of miRNA29s and includes
a, b, and c and differs in one, two, or three bases. These
are clearly enmeshed in the pathogenesis of fibrosis. First
described in fibrosis of the heart by van Rooij et al. in a
landmark study, it has now been demonstrated to play a
major role in fibrosis [3].
Decreased levels of miRNA-29 are associated with fi-
brosis in multiple organs, including the heart, liver [4],
kidney [5] and skin, and in SSc [6], suggesting that this
is a core ‘fibromiRNA’ [7]. In the heart, antagonism of
miRNA-29 in vivo resulted in enhanced collagen in the
tissue, whereas introduction of miRNA-29 mimics after
heart damage reduced the collagen content [3]. Zhu et al.
have also found downregulation of miRNA-29 in SSc
fibroblasts and this correlated with the levels of its tar-
get gene collagen1A1 [8]. Whatever downregulates the
miRNA-29a, this results in a de-repression of its tar-
gets that to date include the major structural collagens.
We have found TAB1 to be a bone fide target of
miRNA-29a in dermal fibroblasts [9]. This gene regu-
lates TIMP-1, which blocks the action of matrix metal-
loproteinases, the enzymes that degrade ECM, and
thus alters the balance of ECM turnover. Dysregulated
TIMP-1 has been previously reported in SSc, and
TIMP-1 is critical in hepatic fibrosis. Indeed, chemical
inhibition of TAB1 also reduced ECM deposition [9],
and we found downregulation of miRNA-29a in SSc fi-
broblasts [9]. MiRNA-29a has also been shown to be
downregulated in SSc and is reduced by Toll-like re-
ceptor (TLR) 4 stimulation [10]. TAB is activated by
TGF-β via the non-canonical pathway [11]. Furthermore,
miRNA-29 has been shown to target platelet-derived
growth factor receptor (PDGFR) [12], and platelet-derived
growth factor signalling is known to be important in fibro-
sis [13]. Interestingly, the miRNA-29 family has been
shown to target the DNA methyltransferases (DNMTs)Pro- or anti-fibrotic Tissue References
Pro Liver [34]
Pro Heart, skin, kidney [22, 23, 63]
Anti Heart, skin, liver [9, 14–17, 20]
Pro Liver [29]
Anti Liver [59]
Anti Skin [39]
Anti Liver [41]
Anti Liver [28]
Pro Kidney [31]
Pro Heart [51]
Pro Lungs, skin [47]
Anti Liver [70]
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reduced miRNA-29 could be targeting DNMTs, thus
leading to hypermethylation and silencing of genes im-
portant in ECM regulation. Cushing et al. also showed
that miRNA-29 regulates a variety of ECM genes that
include the standard ECM proteins such as collagens
and lamins but also integrins that themselves are in-
volved in ECM regulation by activating latent TGF-β
[15]. Furthermore, miRNA-29 is reduced in kidney fi-
brosis and is modulated by TGF-β, and the target of
miRNA-29 was found to be disintegrin metalloprotease
(a disintegrin and metalloproteinase, or ADAM) [16]. It
was also found that miRNA-29 is reduced in lung fibro-
sis in both a TGF-β- and Smad3-dependent manner
[17]. Smad3 genetically reduced mice were protected
from fibrosis induced by bleomycin, confirming its regula-
tion by TGF-β. Importantly, sleeping beauty transponson-
mediated gene transfer of miRNA-29 to replace the
reduced miRNA resulted in an attenuation of fibrosis
[17]. This is an important step as this circumvents the
need for the use of viral vectors that have problems
associated with them, such as triggering host immune
responses to the vector and labour costs. There is a fur-
ther problem with the transduction, and the efficiency
of viral vectors depends on the tropism of the virus for
a particular tissue. A further study showed that diabetic
kidney disease-associated inflammation and fibrosis are
aggravated by genetic renal loss of miRNA-29b in mice,
further underpinning the role of miRNA-29 in fibrosis.
Gene replacement therapy of lost miRNA-29b expression
in the mouse kidney reduced the fibrosis and inflamma-
tion in the diabetic kidney disease model, and the mech-
anism appears to include the TGF-β/Smad3 axis by
modulating this [18]. Upregulation of miRNA-29a either
by enforced overexpression or by the use of carveldilol, a
beta-adrenoreceptor antagonist, was shown to reduce
myocardial fibrosis mediated by experimental myocardial
infarction in a small animal model [19]. Thus, agents that
increase the levels of miRNA-29 would be predicted to
reduce fibrosis. Although many cytokines that decrease
the levels of miRNA-29 have been identified and these
have been found to correlate in vivo, few, if any, cyto-
kines have been found to increase the miRNA. In the
bleomycin model of skin fibrosis, a mimic of SSc, it
was found that miRNA-29a is supressed; however, res-
toration of miRNA-29a levels with the use of the tyro-
sine kinase inhibitor imatinib attenuated this fibrosis
[6], suggesting that miRNA-29a is regulated by tyro-
sine kinase activation. It has recently been shown that
miRNA-29a is also regulated by the alarmin IL-33 [20].
IL-33 is a danger-associated molecule that is released
in tendon disease and this leads to downregulation of
miRNA-29a and a subsequent increase in collagen
levels. Recently, adenoviral overexpression of miR29asystemically injected ameliorated hepatic fibrosis in-
duced by carbon tetrachloride [21].
MiRNAs that modulate TGF-β signalling
Amongst the many cytokines fuelling fibrosis, TGF-β is
one of the most pivotal cytokines mediating fibrosis in
both organ-specific disease and SSc. TGF-β is critical in
fibrosis but also in the development of the organism. It
is elevated in many diseases and animal models of fibro-
sis and affects the activation of quiescent fibroblasts to
‘myofibroblasts’: the effector cells in fibrosis. The myofi-
broblast expresses high amounts of alpha-smooth muscle
actin, secretes copious amounts of ECM and endows the
cell with enhanced contractile force. TGF-β is secreted as
a latent protein non-covalently linked to latency-activating
protein (LAP) and through enzymatic proteolytic cleavage
becomes ‘active’ after dissociating from LAP to bind to its
cognate receptors. TGF-β then mediates gene expression
via activation of the canonical Smad signalling pathway
from transcriptional activation. MiRNAs that regulate
TGF-β would therefore be of prime importance. Only re-
cently have we begun to understand that miRNAs can be
regulated by TGF-β and TGF-β itself can be regulated by
miRNAs. One such miRNA is miRNA-21, which has been
found to be upregulated by TGF-β stimulation. Further-
more, miRNA-21 is overexpressed in heart disease, and in
a pressure overload model it was found that miRNA-21
overexpression modulates cardiac myocyte hypertrophy
and interstitial fibrosis through reduction of sprouty
homologue-1, a potent inhibitor of the extracellular
regulated kinase/mitogen-activated protein kinase (ERK/
MAPK) pathway, and thus elevates this signalling cascade
[22]. In the bleomycin model of fibrosis, this increased
miRNA-21 levels and the addition of antisense oligonucle-
otides to miRNA-21 reduced the severity of lung fibrosis
even after a lag time of many days after lung injury [23].
Knockdown of miRNA-21 reduced pro-fibrotic responses
of TGF-β stimulation, whereas increasing miRNA-21 en-
hanced the pro-fibrotic response [23]. It appears that the
target mRNA of miRNA-21 is Smad7, which is an inhibi-
tory Smad, attenuating the Smad-dependent signalling
pathway. There is, of course, cross-talk between the Smad
and other pathways, adding another layer of complexity.
Smad3 itself regulates the expression of miRNA-21 by
increasing this after stimulation with TGF-β; however,
Smad2 inhibits this. Inhibition of miRNA-21 by ultra-
sound microbubble-mediated gene transfer of a nega-
tive miRNA-21 plasmid attenuated kidney fibrosis in an
obstructive nephropathy model in mice, underscoring
the importance of this miR [24]. MiRNA-21 has also
been demonstrated to be elevated in SSc skin whole tissue
and isolated fibroblasts [8]. Interestingly, miRNA-21 has a
signal transducer and activator of transcription 3 (STAT3)
binding site and this transcriptionally regulates the
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self is an important molecule activated by IL-6 and mediates
fibrosis in SSc fibroblasts [26]. A possible target of miRNA-
21 is the gene phosphatase and tensin homolog (PTEN) and
this abrogates a cell signalling pathway, resulting in in-
creased ECM deposition [27]. It is known that the main
substrate of PTEN is inositol-3,4,5-triphosphate and this ac-
tivates Akt important in wound repair. It is also known that
PTEN is reduced in SSc skin and that PTEN-ablated mice
have exacerbated fibrosis compared with wild-type controls.
Thus, elevated miRNA-21 reduces the expression of PTEN
and this leads to altered Akt signalling, leading to increased
ECM deposition. Interestingly, unsaturated fatty acids ap-
pear to upregulate miRNA-21 levels, inducing the suppres-
sion of PTEN in hepatocytes [27], suggesting a link between
the metabolic syndrome, miRNAs and fibrosis.
TGF-β has been shown to downregulate miRNA-133a
levels in hepatic stellate cells and during hepatic myofi-
broblast development without decreasing stimuli miRNA-
133a levels [28]. Targets of miRNA-133a appear to be
collagens, the major component of the fibrotic scar.
Interestingly, serum expression of miRNA-133a was
found to be elevated in patients with liver fibrosis and
indicated the progression of liver fibrosis [28], indicat-
ing that this could be a valid biomarker where today
none exists. For confirmation of liver fibrosis, often a
biopsy is the only option but this, of course, is invasive.
MiRNA-33a has also been shown to be modulated by
TGF-β in stellate cells, and the potential targets of
miRNA-33a are peroxisome proliferator activator receptor
(PPAR) alpha and Akt in these cells. This is important as
PPAR is critical in the shift from a quiescent to a myofi-
broblast in hepatic stellate cells [29].
MiRNA-192 is also upregulated by the addition of
TGF-β1 and this upregulation promotes collagen depos-
ition in a kidney fibrosis model [30]. Use of antagomirs
to miRNA-192 reduced kidney fibrosis [30]. It appears that
miRNA-192 targets the E-Box repressor Zinc finger E-box
binding homeobox 1 (ZEB1) modulating E-cadherin levels,
enhancing kidney fibrosis [31]. ZEB1 is a critical transcrip-
tion factor in morphogenesis and epithelial-to-mesenchymal
transition [32]. MiRNA-145 is also upregulated by TGF-β
and this leads to increased fibrosis by increasing alpha-
smooth muscle actin levels via activating latent TGF-β [33].
Recently, miR17-5p was found to be induced in hep-
atic stellate cells by TGF-β1 induction and activation
and was also upregulated in the carbon tetrachloride
model of liver fibrosis [34]. In vitro inhibition of miR17-
5p led to reduction of cell activation and proliferation
but no alteration in apoptosis levels [34].
MiRNA-17-92 cluster
The miRNA-17-92 cluster which encodes seven miRNAs is
important in oncogenesis (sometimes called OncomiRNA1),but this cluster also is important in fibrosis. It is critical in
epithelial lung development, and mice that lack this cluster
do not have many lung epithelial cells and die shortly after
birth. Mice in which transgenic overexpression in the lungs
of this miRNA cluster results in lung hyperproliferation and
blocks differentiation of lung progenitor cells were also
demonstrated with transgenic technology [35]. It was found
in idiopathic pulmonary fibrosis samples that miRNA-17-92
cluster was reduced and this was confirmed by both poly-
merase chain reaction and in situ hybridisation techniques.
It was found that there was hypermethylation of DNA in
the promoter region of miRNA-17-92 and that this was
leading to repressed expression of the cluster; the enzyme
DMNT-1 is altered in pulmonary fibrosis and this is also a
target gene of some of the miRNAs in the cluster. Thus, a
complicated feed-forward loop exists in which miRNAs
from the gene cluster target DNMT-1; thus, the reduction
of the miRNAs leads to enhanced DNMT-1 levels. Transfec-
tion of miRNAs reduced DNMT-1 levels and thus globally
methylated DNA levels. Also, in vitro and in vivo adminis-
tration of 5′aza′2-deoxycytidine, a global demethylation
agent, restores the reduction of the miRNA cluster and
reductions in their targets such as collagen1A1 and
CTGF. In vivo treatment of bleomycin-treated mice
after commencement of fibrosis attenuated the fibrosis
in the lungs and also elevated levels of the miRNA clus-
ter under examination. This was accompanied by a re-
duction in DNMT-1 enzyme levels as this is targeted by
the miRNA and also a reduction in pro-fibrotic genes
driving the fibrosis [36]. This cluster has been impli-
cated in liver fibrosis with the bona fide target identi-
fied as CTGF mediated via p53, a tumour-related gene
[37]. CTGF is important as a fibrotic molecule in its
own right and is often associated with TGF-β.
MiRNA-129-5p
In the prototypic fibrotic disease SSc, there is an in-
crease in leucocytes in the skin, including primarily T
cells. These T cells that are residing in the skin are in
close proximity to the myofibroblasts, suggesting that
they are governing their transdifferentiation [38] and may
activate other immune cells in the inflammatory foci. It has
been described in SSc fibroblasts that miRNA-129-5p is re-
pressed compared with healthy control fibroblasts [39].
They also show that the T-cell cytokine IL-17 can increase
miRNA-129-5p levels, and using siRNA to knock down
IL-17 receptors in dermal fibroblasts reduced miRNA-129-
5p levels. The actual target mRNA of miRNA-129-5p ap-
pears to be collagen alpha-1 [39]. This all suggests that the
Th17 cells reduce collagen expression via the upregulation
of the negative regulator miRNA-129-5p; however, in SSc
fibroblasts, the dysregulated TGF-β levels alter the cells’
sensitivity to IL-17, possibly through downregulation of
the TGF-β receptors, thus leading to reduced IL-17
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timately leading to enhanced collagen levels. This hy-
pothesis requires further investigation but may explain
the inconsistent reports on whether IL-17 is pro- or
anti-fibrotic [40]. Increasing knowledge on T cells and
their factors mediating perturbations in miRNAs will
help elucidate these interactions.MiRNA-132
It was found that miRNA-132 regulates the expression
of the methyl cap-binding protein 2 (MeCP2) and that
transdifferentiation of liver fibroblasts into the ‘myofi-
broblast’ of the liver stellate cells is associated with huge
suppression of miRNA-132 [41], suggesting that negative
regulation of MeCP2 is controlled by miRNA-132 ex-
pression. In liver fibrosis models such as the carbon
tetrachloride model, miRNA-132 was reduced, leading
to an upregulation of its target MecP2; this in turn regu-
lates the expression of the methyl enzyme enhancer of
Zeste homologue 2 (Ezh2). This enzyme is a methyltrans-
ferase which methylates histone H3 at lysine 27 and af-
fects transcription of genes. Methylation is associated with
repression of gene expression. This all culminates in a
suppression of PPAR-γ and the brake being ‘released’ on
ECM genes [41] (Fig. 1). This is an example of a complex
interplay between all three epigenetic mechanisms work-
ing in a feed-forward loop and illustrates the cross-talk be-
tween epigenetic modifications. Epigenetic regulation of
such processes is complicated and only now is beginning
to be understood. Because epigenetic modifications are
malleable and modulated by the environment, they can be
modulated by hormones and diet.Fig. 1 miRNA-132 feed-forward loop. Various factors such as IL-6 and dieta
thus lead to increases in its target mRNA meCP2, and meCP2 interacts with
PRC1; this all leads to repression of the master regulator PPARγ and myofib
with DZnep may be beneficial in fibrosis through blocking histone methylation
binding protein 2, miRNA microRNA, PPARγ peroxisome proliferator activator re
growth factor-betaMiRNA-155
Elevated expression of miR-155 has been demonstrated
in alcoholic liver disease in both humans and mice [42].
It is now known that miR-155 is a critical regulator of
the inflammatory response, especially that of the pattern
recognition receptors, the TLRs [43], and is a negative
regulator to limit the response. One of the major ligands
for TLR4 is lipopolysaccharide (LPS) and this has been
found to alter the expression levels of miR-155 [43]. LPS
has been proposed to be a trigger of liver fibrosis
through enhanced translocation of bacteria from a ‘leaky’
gut due to alterations in the gut permeability as a conse-
quence of alcohol provoking an inflammatory and fibrotic
response [44]. In diet-induced obesity models of liver dis-
ease in which the obesity leads to fatty and fibrotic livers,
miR-155 is induced, but under basal conditions the
miR-155 expression profile is low. In mice with miR-155
deleted genetically, these are more susceptible to diet-
induced fatty liver disease as compared with wild-type
mice [45] and the target of this is the liver X receptor [45].
The liver X receptor modulates lipid deposition genes and
the hypothesis is that miR-155 upregulation is a protective
mechanism due to targeting the liver X receptor and
thereby supressing its expression and downstream genes.
It was recently demonstrated in liver disease that miR-155
is elevated, confirming previous reports, and that this is
altered in stellate cells [46]. Importantly, the miR alters
ERK and inhibiting miR-155 stimulates the fibrotic
response.
MiRNA-199a
Very recently, miRNA-199a-5p was also found to be
upregulated in lung fibrosis. Interestingly, the elevatedry factors, including alcohol, reduce the expression of miRNA-132 and
the methylase Ezh2 that methylates lysine27 on H3 and interacts with
roblast activation and extracellular matrix expression. Blockade of Ezh2
. Ezh2 enhancer of Zeste homologue 2, IL interleukin, MeCP2 methyl cap-
ceptor-gamma, PRC1 polycomb recessive complex 1, TGF-β transforming
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not adjacent non-myofibroblast cells [47]. In a quest to
identify targets, the authors used a gene array approach
and found that caveolin-1 was a target and this was
confirmed by using luciferase assays that had mutated
binding sites, confirming this as a true target of miRNA-
199a-5p [47]. Caveolin-1 is itself a target of the pro-fibrotic
cytokine TGF-β, and in three different models of different
organ fibrosis, it turns out that miRNA-199a-5p is com-
monly dysregulated. This suggests that this miRNA is a
core regulator of fibrosis. It is of interest that caveolin-1 is
a target of miRNA-199a-5p because caveolin-1 is part of
caveolae, which are bulb-shaped invaginations on the cell
membrane, around 50–100 nm, and are involved in cell
signalling and trafficking. Caveolin-1 mediates TGF-β sig-
nalling by internalising the TGF receptors into caveolae
and this internalisation by these buds leads to degradation
and blunting of the signal and thus less Smad activation. It
was found that Caveolin-1 protein expression is reduced in
the skin and lungs of patients with SSc, and reconstitution
of the reduced caveolin-1 reduced the expression of key
ECM [48]. Single-nucleotide polymorphisms have also
been found to be associated with caveolin-1 and fibrosis
[49]. Reduced caveolin-1 is associated with idiopathic
pulmonary fibrosis and this enhanced TGF-β signalling
through modulation of the MAPK pathway [50]. There
is now clear evidence that miRNA-199 is involved in fi-
brosis and is a therapeutic target, and further fibrosis
animal models will glean more information on clinical
utility.Fig. 2 miRNA modulation. Two methods are employed for miRNA therapeut
use of double-stranded RNA, which is composed of a guide and passenger st
The guide strand is identical to the miRNA that is diminished. This is then
Inhibition of miRNA function is achieved through single-stranded chemic
and have increased stability. These molecules bind the mature miRNA an
the mRNA target(s). In the context of fibrosis, to the right of the illustratio
the target mRNA and altering the protein output. Smad7 is a negative re
PPAR-α is also a negative regulator of fibrosis and thus its restoration is p
receptor-alpha, RISC RNA-induced silencing complexMiRNA-199b
Recent studies revealed that miRNA-199b is an important
miRNA in mediating fibrosis. It was shown to be elevated in
heart disease and in hypertrophy models on heart dis-
ease. It targets dual-specificity tyrosine (Y) phosphorylation-
regulated kinase-1a (dyrk1a), which alters calcenurin
levels and modulates the signalling through NFAT.
Genetically modified mice that overexpress miRNA-199b
have enhanced myocardial fibrosis, and in vivo use of an
antagomir against miRNA-199b in vivo reduced myocar-
dial fibrosis in multiple models of heart disease [51].
Modulation of miRNAs for therapeutic gain
Genetic ablation studies of specific miRNAs in animal
models and also in vitro activation or inhibition have
established miRNAs as an attractive target for therapeutic
modulation in multiple diseases [52] (Fig. 2). MiRs are
appealing therapeutically since multiple similar path-
ways can be targeted at once because each miRNA tar-
gets multiple mRNAs and the molecules are small and
easily chemically modified. Also, miRs are often conserved
across species and so the same oligos can be used in
animal models. Chemical modifications to the miRNAs
include locked nucleic acid (LNA) technology in which
the ring in the sugar phosphate backbone is chemically
locked by the introduction of a 2′-O,4′-C-methylene
bridge. This increases the stability of the molecule and
resistance to breakdown via endogenous nucleases. RNA
itself is rather unstable. LNA technology modification in-
creases the RNA melting temperature by 2.4 °C per LNAics restoration of miRNA or inhibition. Restoring miRNA is through the
rand that is chemically modified usually by a cholesterol modification.
incorporated into the RISC complex and the target mRNAs reduced.
ally modified LNA antagomirs which can be cholesterol-conjugated
d stop them from being loaded into the RISC, therefore increasing
ns are examples of miRNA as both a mimic and antagomir binding
gulator of the fibrotic cascade, so elevated levels reduce fibrosis.
ositive. miRNA, MicroRNA, PPARα peroxisome proliferator activator
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the nucleic acid to the mRNA [53]. LNA-modified antago-
mirs were first used in vivo in non-human primates to
target the liver miRNA-122 and resulted in a sustained
and long-lasting decrease in cholesterol [54]. Injection
of unmodified miRNAs into the tail vein of mice results
in breakdown and renal excretion very quickly [55]. A
different chemical modification is a 2′O-methyl modifi-
cation that increases nuclease resistance. Another chem-
ical modification is the addition of a cholesterol moiety at
the 3′ end. Despite the theoretical rationale for modula-
tion, only one antagomir is currently in clinical use. This
is the antagomir for miRNA-122, marketed as Miravirsen
(Roche, Copenhagen, Denmark), and has shown great
clinical efficacy [56]. Miravirsen targets miRNA-122,
which is a liver-specific miRNA and thus is not expressed
anywhere else; it uses LNA technology. It works by block-
ing the interaction with the miRNA (122) and its target
RNA in the hepatitis C virus (HCV) 5′ UTR [57].
MiRNA-122 is essential for the replication of HCV [58]
and lipid and iron metabolism in the liver [59]. It appears
safe and well tolerated and has no adverse effects. Another
approach to targeting miRNAs is termed tiny LNAs.
These are tiny (8-mer) LNA anti-miRNAs that target only
the conserved seed region [60]. An alternative strategy is
the use of miRNA masking (miRNA-Mask); this works by
the introduction of single-stranded RNA that targets the
3′ UTR of the protein coding mRNA and thus ‘covers up’
the binding site to the miRNA and thereby de-represses
the protein target. This technology has been used to con-
firm targets of miRNAs in vitro. Further study is needed
to determine which chemical modification is optimum for
stability without undue toxicity. Another way of targeting
miRNAs in fibrosis is to reconstitute reduced levels of the
miRNA with miRNA replacement, thus restoring the sup-
pression of the putative target(s). The introduction of such
miRNA mimic replacement can occur through the direct
introduction of the mimic or the use of viral vectors to ex-
press the miRNA. Viral vectors, however, may induce an
unwanted immune response, and tissue tropism may limit
their effectiveness. Therapeutically, antagomirs are much
more advanced than miRNA replacement therapy. One
issue that is currently hampering the field is that the
introduction of miRNA therapeutics is not cell- or
organ-specific and thus being systemic may have major
side effects. Getting the miRNA therapeutic to the cor-
rect target tissue remains a challenge, especially if
injected systemically; getting the miRNA out of the cir-
culatory system and crossing the endothelium will be
challenging if over 5 nm in diameter. One recent study
used a neutral lipid emulsion as a vehicle for the sys-
temic delivery of miRNA-34a, which is downregulated
in cancer, and this lipid vehicle delivery system was cap-
able of reducing lung tumour burden in a mouse model oflung cancer [61]. It is suggested that the use of a neutral
lipid vehicle does not aggregate so much and is less likely
to be engulfed by macrophages [61]. As further delivery
systems are developed for miRNAs to target them more
specifically to the target tissue and cells, further wide-
spread use will occur. A further issue with the blockade of
miRNAs with antagomirs may be that the levels of redun-
dancy may restrict the therapeutic benefit.
The vista is optimistic for using miRNAs therapeutic-
ally to treat fibrotic conditions such as SSc. This is one
of the fastest growing areas in scientific research and
offers the potential to revolutionise treatment. It was
shown in an animal model of kidney fibrosis that the use
of an antagomir to miRNA-214 attenuated kidney fibro-
sis [62] and that this is independent of classic TGF-β
signalling.
One of the most studied fibrotic miRNAs is miRNA-21,
and use of an antagomir in two mouse models of kidney
fibrosis demonstrated great clinical efficacy in reducing fi-
brosis [63]. Mechanistically, it was found that miRNA-21
targets the 3′ UTR of PPAR-α, an important receptor in
involved in lipid metabolism; indeed, deletion of PPAR-α
abrogated the effect of anti-miRNA-21 anti-fibrotic effects
[63]. The authors further demonstrated that mitochon-
drial oxidative regulators are also a target of miRNA-21
[63], suggesting that metabolic stress is important in fi-
brosis generation. Regulus Therapeutics (San Diego, CA,
USA) also has an antagomir against miRNA-21 (RG-012)
in the developmental pipeline and this antagomir showed
good efficacy in animal models of Alport syndrome, an
inherited kidney disease in which mutations in collagen
lead to excess collagen deposition within the kidney.
Replacing reduced miRNAs
Replacement of reduced miRNA expression by using miRNA
mimics could be one therapeutic strategy in fibrosis.
This involves the use of RNA duplexes in which there
is a ‘guide strand’ and a passenger strand that may be
chemically modified. Although restitution of miRNAs is
in its infancy, it has been proven in animal models of
cancer and more recently fibrosis. Often restoring the
lost miRNA is achieved by viral vectors. This has its
own challenges, as the vector size may be large and sys-
temic delivery may be difficult to achieve and can also
have high immunogenicity. Montgomery et al. recently
published the use of a miRNA-29 mimic in an animal
model of fibrosis, the bleomycin lung fibrosis model, and
showed that introduction of the miRNA mimic in vivo
was effective in reducing this fibrosis [64] and confirmed
reductions in the miRNAs target proteins. But what is
more impressive is that introduction of the mimic was
effective in prevention of fibrosis with no observable
side effects [64]. miRagen Therapeutics (Boulder, CO, USA)
has an miRNA-29 mimic in pre-clinical development for
O’Reilly Arthritis Research & Therapy  (2016) 18:11 Page 8 of 10fibrotic conditions and uses a non-viral vector for systemic
delivery. miRagen Therapeutics should move into clinical
trials soon with this molecule. (Table 2 illustrates miRNA
therapeutics in development.)
Although miR therapeutics is a promising area, chal-
lenges do remain. These include the effective delivery of
the mimic or antagomirs targeted to the correct tissue
and cell type. Strategies to do so include viral vector de-
livery, liposomes and nanoparticle delivery. Of course,
some tissues such as the skin and lung are more access-
ible than others. The use of ligands that are attached to
the nucleotides that are specific for certain cell surface
receptors that bind and then internalise may be one way
of enhancing specific cell uptake. Here, they can release
their ‘cargo’. A major concern is also ‘off target effects’
of the miR therapeutics. A principle benefit of targeting
miRNAs is that they often target mRNAs in the same
pathway and so fine-tune the output of a particular path-
way; however, this may be a wanted effect in one specific
cell type but not in another cell type. A further consider-
ation should be drug resistance, as in cancer treatment
drug resistance can develop; this itself can be mediated
through miRs, altering gene expression of mRNAs critical
in driving this effect. It could be speculated that, in miR
therapeutics, antagomir therapy may reduce the miR and
thus increase its targets, but mechanisms to counter this
through upregulation of the miR being targeted by in-
creased biogenesis may lead to diminishing effectiveness.
Finally, the TLR system can also respond to RNA and in-
duce an antiviral response through downstream adaptor
proteins and this could be theoretically activated by miRs.
Serum miRNAs as diagnostic/prognostic markers
MiRNAs appear remarkably stable in serum and other
bodily fluids such as urine and saliva [65]; this is because
they are enclosed in extracellular membrane-bound vesi-
cles or combined with high-density lipoproteins. Thus,
they are attractive as a non-invasive diagnostic biomarker
of disease. There are associations with various cytokines
in fibrotic diseases; however, none of these is sufficiently
robust to be diagnostic or guide treatment. The hepatic-
specific miRNA-122, which is the target of miravirsen, has
been shown to be reduced in hepatic fibrosis in cells [66];
however, the circulating serum levels of miRNA-122 areTable 2 MicroRNA therapeutics in fibrosis
Company MicroRNA target Stage
Regulus Therapeutics 21 (RG-012)/Antagomir Phase 1 clinical trial
Alport syndrome
miRagen Therapeutics 29 mimic Pre-clinical
development
miRagen Therapeutics 155a mimic Pre-clinical
Marina Biotech 21 Antagomir Pre-clinical
aAlthough developed for immune modulation could be useful in fibrosiselevated significantly in fibrosis and this correlates with
serum alanine aminotransferase (ALT) levels, a marker of
damaged liver [67] and may be a more reliable marker
than ALT in assessing fibrosis [67] and has been found in
other independent cohorts [68]. It has been suggested that
serum miRNA-122 is elevated in hepatocyte injury regard-
less of the aetiology [69] and this may prevent it being
used specifically for liver fibrosis. miRNA-214 has also
been found extracellularly and to actually mediate signals
through downregulation of its target gene CTGF via extra-
cellular exosomes to target cells mediating fibrosis [70].
This has also been shown in in vitro models and in vivo
[71]. It now appears that exosome mediates the transfer of
miRNAs to distal cells to trigger intracellular signalling
and that exosomes display cell surface markers that the
target can recognise and internalise through receptors,
thereby giving rise to direct mRNA repression. The im-
portant fibrotic miRNA-29a has also been found in the
serum to be associated with cardiac fibrosis in cardiac
hypertrophy [72]. In SSc, a few circulating miRNAs have
been demonstrated to be higher in serum compared with
controls, including miRNA-142-3p [73]. Furthermore,
miRNA-196a has been demonstrated to be reduced in
SSc serum compared with healthy controls [74]. There
was also a correlation between lower serum miRNA-196a
levels and the modified Rodnan skin score, which is a
measurement of skin thickness due to fibrosis [74]. In-
deed, levels of miRNA-196a have also been found to be
differentially expressed in the hair of patients with SSc
[75]. Although miRNAs in serum have been demonstrated
in association with fibrotic organ-specific diseases or in
SSc, their clinical utility remains to be determined, and
larger studies are needed to validate these reports. Stratifi-
cation of patients on the basis of specific miRNAs may
allow a more targeted therapeutic approach. Furthermore,
in the case of serum miR, there is no consensus yet on the
‘normalisation’ method used for these studies. Tissue-
based markers of miR expression are of limited value as
whole tissue comprises multiple cell types and miRs are
cell-type dependent. The additional effort to isolate single
cells yields much more informative results.
Conclusions
Since their discovery two decades ago, miRNAs have
been found to be associated with various diseases. There
is currently good evidence for the role of miRNAs in fi-
brotic diseases, either organ-specific or systemic fibrosis,
such as SSc. Important steps have been made in recent
years, including the identification of dysregulated miRNAs
and their targets. Whereas the exact targets of these
miRNAs are unknown for some, they are known for
others, and they are regulating key downstream pathways
in disease pathogenesis such as miRNA-29, which is a key
mediator of fibrosis. Gene therapy with the restoration of
O’Reilly Arthritis Research & Therapy  (2016) 18:11 Page 9 of 10miRNA-29, at least in an animal model of fibrosis, appears
to reduce fibrosis [18]. Currently, many companies are
looking at using miRNA technologies for modulating
various fibrotic conditions. By far the most advanced is
antagomirs to block the function of an miRNA and thus
increase its target transcript and signalling pathway. How-
ever, recent data are emerging on the role of increasing
miRNAs in vivo, especially miRNA-29a, to restore its
function and thus suppress fibrosis without the need
for viral vectors. There are some problems, such as sta-
bility of the miRNAs and tissue targeting, but if these
are overcome, therapeutic modulation of miRNAs may
become a clinical reality in fibrosing conditions, which
is a huge unmet clinical need. The use of vehicles to
target specific tissues and cells is important to direct
where the target should be modulated, and optimisation
of such vehicles is critical. Inherent to understanding the
manipulation of miRNAs is a deeper understanding of the
targets of miRNAs and the regulation of their expression
in vivo. Caution must be taken when interpreting the
expression of miRNAs in tissues as miRNAs are cell
type-specific and the value of whole tissue expression
such as skin may be questionable. Techniques such as
laser capture micro-dissection in which individual cells
can be captured are more useful in deriving meaningful
results of miRNA analysis. In heterogeneous diseases such
as SSc or liver fibrosis, it may be that the clinical
course of the disease is dictated by the expression of
miRNAs, which themselves are plastic and altered by
the environment.
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